

Separation of Desvenlafaxine Succinate and its Organic Impurities per USP Monograph

Waleed Afaq, Zeshan Aqeel, and Bryan Tackett, PhD Phenomenex Inc., 411 Madrid Ave., Torrance, CA 90501, USA



Desvenlafaxine Succinate is a serotonin-norepinephrine reuptake inhibitor (SNRI). It increases serotonin and norepinephrine activity in the brain, which helps regulate mood. The development of a quick and efficient analysis of Desvenlafaxine Succinate and its organic impurities is of interest for generic drug manufacturers. In this application note, we report the separation of Desvenlafaxine Succinate and its related organic impurities using a Luna[™] Omega 3 μm C18 column according to the USP monograph for Desvenlafaxine Succinate.

System suitability per USP Monograph for the Desvenlafaxine Succinate Organic Impurities is a resolution no less than (NLT) 1.5 between Desvenlafaxine Related Compound B and Desvenlafaxine Succinate, a percent relative standard deviation (%RSD) no more than 5 % for Desvenlafaxine Succinate, and a signal-to-noise (S/N) ratio of NLT 10 for Desvenlafaxine Succinate. The area %RSD was 0.612 % for Desvenlafaxine Succinate using the Luna Omega 3 μ m C18 column (**Figure 2**). The resolution between Desvenlataxine Related Compound B and Desvenlafaxine Succinate was 3.05 (**Figure 3**) and the S/N ratio was 77.3 for Desvenlafaxine Succinate using the Luna Omega 3 μ m C18 column (**Figure 4**). All requirements for System Suitability for Desvenlafaxine Succinate Organic Impurities were met by the Luna 3 μ m C18 column.

All solutions were prepared as indicated in the USP Monograph for Desvenlafaxine Succinate. USP Desvenlafaxine Succinate RS (Catalog No. 1175773) and Desvenlafaxine Related Compound B (Catalog No. 1175795) were purchased from USP.

Figure 1. Desvenlafaxine Succinate



LC-UV Conditions

Column: Luna Omega 3 µm C18

Dimension: 250 x 4.6 mm **Part No.:** <u>00G-4784-E0</u>

Mobile Phase: A: Acetonitrile/Buffer (10:90, v/v)

B: Acetonitrile/Buffer (60:40, v/v)

Buffer: 7.1 g/L of Anhydrous Dibasic Sodium Phosphate in water, adjusted to pH 3.0 with

Phosphoric Acid

Gradient: Time (min)	%В
0	0
5	0
30	50
35	65
37	0

Flow Rate: 1.5 mL/min Injection Volume: 20 μL Temperature: 50 °C


Detector: UV @ 225 nm

System: Agilent® 1260 Binary UHPLC

Table 1. Preparation of Solutions


Solution	Composition
Diluent	Mobile Phase A
Standard Solution	0.001 mg/mL of USP Desvenlafaxine Succinate RS in Diluent. Sonication may be used to promote dissolution.
System Suitability Solution	1 mg/mL of USP Desvenlafaxine Succinate RS and 0.0015 mg/mL of USP Desvenlafaxine Related Compound B RS in Diluent. Sonication may be used to promote dissolution.
Sensitivity Solution	$0.5~\mu g/mL$ solution made by diluting Standard Solution by a factor of 2 in Diluent.

Figure 2. Standard Solution




Peak No.	Analyte	Retention Time (min)	Area %RSD	
1	Desvenlafaxine Succinate	18.19	0.612	
N = 6 Injections				

Figure 3. System Suitability Solution



Peak No.	Analyte	Retention Time (min)	Resolution	
1	Desvenlafaxine Related Compound B	17.69	2.05	
2	Desvenlafaxine Succinate	18.88	3.05	
N = 6 Injections				

Figure 4. Sensitivity Solution



Peak No.	Analyte	Retention Time (min)	S/N Ratio
1	Desvenlafaxine Succinate	17.37	77.3
N = 3 Injections			

Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/Chat.

Australia t: +61 (0)2-9428-6444 auinfo@phenomenex.com

Austria t: +43 (0)1-319-1301 anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch) beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681 info@phenomenex.com

China

t: +86 400-606-8099 cninfo@phenomenex.com

Czech Republic

t: +420 272 017 077 cz-info@phenomenex.com

t: +45 4824 8048 nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063 nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10 franceinfo@phenomenex.com

Germany t: +49 (0)6021-58830-0 anfrage@phenomenex.com

Hong Kong t: +852 6012 8162

hkinfo@phenomenex.com

India

t: +91 (0)40-3012 2400 indiainfo@phenomenex.com

Indonesia

t: +62 21 5010 9707 indoinfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405 eireinfo@phenomenex.com

Italy t: +39 051 6327511 italiainfo@phenomenex.com

Japan

t: +81 (0) 120-149-262 ipinfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700 nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226 tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700 nlinfo@phenomenex.com

New Zealand t: +64 (0)9-4780951 nzinfo@phenomenex.com

t: +47 810 02 005 nordicinfo@phenomenex.com

t: +48 22 104 21 72 pl-info@phenomenex.com

Portugal

t: +351 221 450 488 ptinfo@phenomenex.com

Singapore

t: +65 800-852-3944 sginfo@phenomenex.com

Slovakia

t: +420 272 017 077 sk-info@phenomenex.com

Spain t: +34 91-413-8613 espinfo@phenomenex.com

t: +46 (0)8 611 6950 nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20 swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246 twinfo@phenomenex.com

Thailand

t: +66 (0) 2 566 0287 thaiinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367 ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555 info@phenomenex.com

All other countries/regions Corporate Office USA

t: +1 (310) 212-0555 info@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com



Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Luna and BE-HAPPY are trademarks of Phenomenex. Agilent is a registered trademark of Agilent Technologies, Inc. Disclaimer

Phenomenex is in no way affiliated with Agilent Technologies, Inc.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures. © 2022 Phenomenex, Inc. All rights reserved.